Skip To Main Content
Yingtong Chen on Muck Rack

Yingtong Chen

As seen in: Nature, Wiley Online Library, Frontiers, MDPI, Canadian Journal of Infectious Diseases & Medical Microbiology, Asian Nursing Research
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Yingtong

Contact Yingtong, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Inhibition of ERK5 activity ameliorates osteoarthritis by suppressing NLRP3 inflammasome-mediated chondrocyte pyroptosis

|
By Baolin Zhang, Deying Su, Hengyu Liu, Gengjia Chen, Yingtong Chen, Guanhong Chen, Zhiheng Liao, Taifeng Zhou, Shuqing Chen, Peiqiang Su, Caixia Xu, Peihang Fang, Jiahui Long, Ricong Weng
| Nature Verified
Abstract Osteoarthritis (OA) is a widespread degenerative joint disorder manifesting as chronic pain, functional impairment, and progressive disability, imposing a substantial burden on global public health. Despite extensive research, the precise molecular pathways underlying OA pathogenesis remain incompletely elucidated.
Open in Who Shared Issue with article?

CD73 inhibitor enhances the antitumor activity of selinexor in multiple myeloma by restoring the activation of CD8 + T cells

|
By Chunli Zhang, Qiuxia Wei, Gang Bian, Chaoling Wu, Jing L. Wang, Ping Yang, Jiahui Hua, Mingxia Zhu, Yingtong Chen, Yan Liu, Shuang Gao, Bing Hou, Weilong Zhang, Hongmei Jing, Nigmat Rahim
| Nature Verified
Abstract Selinexor, a selective nuclear export inhibitor, blocks exportin-1 and reduces oncoprotein messenger RNA translation, and is approved for the treatment of relapsed/refractory multiple myeloma in combination with proteasome inhibitors, immunomodulators, anti-CD38 antibodies, etc. Nevertheless, selinexor presents limited monotherapy efficacy with an objective response rate of 29% and fails to completely overcome drug resistance.
Open in Who Shared Issue with article?

BIRC5 drives cell-cycle dysregulation and represents a novel molecular target in retinoblastoma

|
By Yingtong Chen, Xiaohan Li, Fuhua Zhong, Xiaoya Wang, Qiang Wang, Di Cao, Shaowei Dong, Chengyue Zhang, Huibin Song, Chen Lin Verified
| Frontiers
Abstract Aims and objectives: Retinoblastoma is the most common pediatric intraocular malignancy, although it remains a rare disease overall, yet the molecular targets and therapeutic vulnerabilities sustaining its most aggressive proliferative cell states remain incompletely defined. We aimed to identify actionable molecular regulators and potential therapeutic targets of malignant retinoblastoma progression using integrated single-cell transcriptomics and functional validation.
Open in Who Shared Issue with article?
See all 10 licensed articles (11 Total)